Philips touts adaptive servo ventilation sleep apnea study data

Royal Philips (NYSE:PHG) yesterday released results from a study exploring the use of adaptive servo ventilation in treating patients with complex sleep apnea. Results from the study were published in the American Journal of Respiratory and Critical Care Medicine, the Amsterdam-based company said. Investigators in the study compared the performance of four different ASV devices, including Philips’ DreamStation BiPap autoSV, as well as an ASV device originally associated with greater mortality during the SERVE-HF trial published in 2015, the company said. “The pursuit for scientific understanding of various disease and treatment processes is an iterative process where we revisit successes and failures to deepen our understanding of disease processes. It’s imperative we keep this in mind and re-visit previous studies when technological advancements show promise for a certain type of therapy. Today, ASV isn’t used in certain clinical settings due to safety concerns associated with the therapy in patients with congestive heart failure and predominantly central sleep apnea. Now, through devices with smarter algorithms, providers can potentially ensure that patients are getting the right treatment and thereby improve treatment approaches in patients with complex or central sleep apnea,” lead study investigator Dr. Sairam Parthasarathy of the University of Arizona College of Medicine said in a prepared statement. Data from the new trial suggests that certain p...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Respiratory Royal Philips Source Type: news